Twist Bioscience HQ
681 Gateway Blvd
South San Francisco, CA 94080
Next-Generation Sequencing (NGS) of cell-free DNA (cfDNA) has emerged as a promising strategy for early detection,diagnosis, and monitoring of cancer progression. In this process, cfDNA is extracted from a patient’s blood and undergoes library preparation prior to NGS. The challenge with cfDNA library preparation is reliably capturing and converting all the fragmented DNA, especially when present in low concentrations within biological samples. Attaining low variant detection thresholds and variant calling confidence demands high-performance NGS libraries and targeted sequencing protocols.
Technical Document